PHIO Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2023-06-09 | 2022 | Gerrit Dispersyn, Dr. Med. Sc. Former President and Chief Executive Officer | 178,514 | 0 | 108,511 | 0 | 202,744 | 489,769 |
| 2023-06-09 | 2021 | Geert Cauwenbergh, Dr. Med. Sc. Former interim Principal Executive and Financial Officer | 27,500 | 0 | 30,800 | 0 | 0 | 58,300 |
| 2023-06-09 | 2022 | Geert Cauwenbergh, Dr. Med. Sc. Former interim Principal Executive and Financial Officer | 68,750 | 0 | 8,612 | 0 | 0 | 77,362 |
| 2023-06-09 | 2021 | Robert J. Bitterman President and Chief Executive Officer | 47,500 | 0 | 30,800 | 0 | 0 | 78,300 |
| 2023-06-09 | 2022 | Robert J. Bitterman President and Chief Executive Officer | 77,885 | 0 | 31,464 | 0 | 31 | 109,380 |
| 2023-06-09 | 2021 | Gerrit Dispersyn, Dr. Med. Sc. Former President and Chief Executive Officer | 403,390 | 0 | 210,826 | 136,688 | 575 | 751,479 |
| 2022-06-30 | 2022 | Jonathan E. Freeman, Ph.D. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2022-06-30 | 2022 | Curtis A. Lockshin, Ph.D. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2022-06-30 | 2022 | Geert Cauwenbergh, Dr. Med. Sc. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2022-06-30 | 2022 | Robert L. Ferrara | 0 | 0 | 0 | 0 | 0 | 0 |
| 2022-06-30 | 2022 | Robert J. Bitterman | 0 | 0 | 0 | 0 | 0 | 0 |
| 2022-06-30 | 2022 | Patricia A. Bradford | 0 | 0 | 0 | 0 | 0 | 0 |
| 2021-04-30 | 2021 | Jonathan E. Freeman, Ph.D. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2021-04-30 | 2021 | Curtis A. Lockshin, Ph.D. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2021-04-30 | 2021 | Robert J. Bitterman | 0 | 0 | 0 | 0 | 0 | 0 |
| 2021-04-30 | 2021 | Geert Cauwenbergh, Dr. Med. Sc. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2021-04-30 | 2021 | Gerrit Dispersyn, Dr. Med. Sc. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2021-04-30 | 2021 | H. Paul Dorman | 0 | 0 | 0 | 0 | 0 | 0 |
| 2021-04-30 | 2021 | Robert L. Ferrara | 0 | 0 | 0 | 0 | 0 | 0 |
| 2020-08-28 | 2020 | Robert J. Bitterman | 0 | 0 | 0 | 0 | 0 | 0 |
| 2020-08-28 | 2020 | Geert Cauwenbergh, Dr. Med. Sc. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2020-08-28 | 2020 | H. Paul Dorman | 0 | 0 | 0 | 0 | 0 | 0 |
| 2020-08-28 | 2020 | Robert L. Ferrara | 0 | 0 | 0 | 0 | 0 | 0 |
| 2020-08-28 | 2020 | Jonathan E. Freeman, Ph.D. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2020-08-28 | 2020 | Curtis A. Lockshin, Ph.D. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2019-08-30 | 2018 | Geert Cauwenbergh, Dr. Med. Sc. Former Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2019-08-30 | 2017 | Gerrit Dispersyn, Dr. Med. Sc. President and Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2019-08-30 | 2018 | Gerrit Dispersyn, Dr. Med. Sc. President and Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2019-08-30 | 2017 | Geert Cauwenbergh, Dr. Med. Sc. Former Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2018-04-26 | 2018 | Jonathan E. Freeman, Ph.D. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2018-04-26 | 2018 | Geert Cauwenbergh, Dr. Med. Sc. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2018-04-26 | 2018 | Robert J. Bitterman | 0 | 0 | 0 | 0 | 0 | 0 |
| 2018-04-26 | 2018 | Keith L. Brownlie | 0 | 0 | 0 | 0 | 0 | 0 |
| 2018-04-26 | 2018 | H. Paul Dorman | 0 | 0 | 0 | 0 | 0 | 0 |
| 2018-04-26 | 2018 | Curtis A. Lockshin, Ph.D. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2017-04-27 | 2016 | Geert Cauwenbergh, Dr. Med. Sc. President, Chief Executive Officer and acting Chief Financial Officer | 413,723 | 0 | 0 | 197,600 | 624 | 638,549 |
| 2017-04-27 | 2015 | Pamela Pavco, Ph.D. Chief Development Officer | 363,808 | 0 | 0 | 104,025 | 300 | 486,613 |
| 2017-04-27 | 2016 | Pamela Pavco, Ph.D. Chief Development Officer | 377,522 | 0 | 0 | 108,186 | 585 | 499,493 |
| 2017-04-27 | 2015 | Geert Cauwenbergh, Dr. Med. Sc. President, Chief Executive Officer and acting Chief Financial Officer | 398,361 | 0 | 0 | 190,000 | 300 | 625,901 |
| 2016-11-04 | 2016 | Curtis A. Lockshin, Ph.D. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2016-11-04 | 2016 | Geert Cauwenbergh, Dr. Med. Sc. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2016-11-04 | 2016 | Robert J. Bitterman | 0 | 0 | 0 | 0 | 0 | 0 |
| 2016-11-04 | 2016 | Keith L. Brownlie | 0 | 0 | 0 | 0 | 0 | 0 |
| 2016-11-04 | 2016 | H. Paul Dorman | 0 | 0 | 0 | 0 | 0 | 0 |
| 2015-04-16 | 2015 | Geert Cauwenbergh, Dr. Med. Sc. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2015-04-16 | 2015 | Robert J. Bitterman | 0 | 0 | 0 | 0 | 0 | 0 |
| 2015-04-16 | 2015 | Keith L. Brownlie | 0 | 0 | 0 | 0 | 0 | 0 |
| 2015-04-16 | 2015 | H. Paul Dorman | 0 | 0 | 0 | 0 | 0 | 0 |
| 2015-04-16 | 2015 | Curtis A. Lockshin, Ph.D. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2014-04-15 | 2014 | Robert J. Bitterman | 0 | 0 | 0 | 0 | 0 | 0 |
| 2014-04-15 | 2014 | Geert Cauwenbergh, Dr. Med. Sc. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2014-04-15 | 2014 | Curtis A. Lockshin, Ph.D. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2014-04-15 | 2014 | H. Paul Dorman | 0 | 0 | 0 | 0 | 0 | 0 |
| 2014-04-15 | 2014 | Keith L. Brownlie | 0 | 0 | 0 | 0 | 0 | 0 |
| 2013-04-26 | 2013 | Curtis A. Lockshin, Ph.D. | 0 | 0 | 0 | 0 | 0 | 0 |
| 2013-04-26 | 2013 | Robert J. Bitterman | 0 | 0 | 0 | 0 | 0 | 0 |
| 2013-04-26 | 2013 | Keith L. Brownlie | 0 | 0 | 0 | 0 | 0 | 0 |
| 2013-04-26 | 2013 | H. Paul Dorman | 0 | 0 | 0 | 0 | 0 | 0 |
| 2013-04-26 | 2013 | Geert Cauwenbergh, Dr. Med. Sc. | 0 | 0 | 0 | 0 | 0 | 0 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
